The Gut Microbiome in Hyperuricemia and Gout

Area of Science:

• Microbiology
• Gastroenterology
• Nephrology

Background:

• Hyperuricemia and gout result from decreased urate elimination and excess production.
• Chronic kidney disease (CKD) impairs renal urate elimination, increasing reliance on gut elimination.
• Gut microbiota play a role in purine metabolism and urate disposition.

Purpose of the Study:

• To investigate the urate-lowering capacity of gut bacteria.
• To explore the potential of purine-degrading bacteria (PDB) as a novel therapeutic approach for gout.
• To understand the impact of gut microbiota on urate levels in the context of CKD.

Main Methods:

• Preclinical studies in mice with impaired uricase activity.
• Human studies involving antibiotic-induced gut microbiota depletion.
• Analysis of gut microbiota composition in gout cohorts.

Main Results:

• Gut microbiota, particularly purine-degrading bacteria (PDB), can significantly lower urate levels.
• PDB possess a unique gene cluster for converting urate to lactate or short-chain fatty acids.
• Microbiota depletion increases urate levels, while PDB administration reverses this effect.
• Antibiotic use and gut dysbiosis, including Bacillota depletion, are linked to gout risk.

Conclusions:

• Diverse gut bacteria can biochemically compensate for human limitations in urate disposition.
• Novel probiotic treatments targeting gut microbiota offer potential for managing gout flares and hyperuricemia.
• This approach is particularly promising for patients with severe CKD and limited conventional treatment options.